Multiple pathways have been proposed to explain how proteasome inhibition induces cell death, but mechanisms remain unclear. To approach this issue, we performed a genome-wide siRNA screen to evaluate the genetic determinants that confer sensitivity to bortezomib (Velcade (R); PS-341). This screen identified 100 genes whose knockdown affected lethality to bortezomib and to a structurally diverse set of other proteasome inhibitors. A comparison of three cell lines revealed that 39 of 100 genes were commonly linked to cell death. We causally linked bortezomib-induced cell death to the accumulation of ASF1B, Myc, ODC1, Noxa, BNIP3, Gadd45α, p-SMC1A, SREBF1, and p53. Our results suggest that proteasome inhibition promotes cell death primarily by dysregulating Myc and polyamines, interfering with protein translation, and disrupting essential DNA damage repair pathways, leading to programmed cell death. Cancer Res; 70(11); 4318-26. ©2010 AACR.
Introduction
The primary targets of most cancer chemotherapies are known. However, the downstream effect on the cell is generally poorly understood, particularly the sequence of events directly involved in the commitment of the tumor cell to die. This lack of knowledge is particularly profound for proteasome inhibition because the majority of intracellular proteins can be degraded by the proteasome. As such, simply showing that proteasome inhibition can result in the stabilization of a protein does not necessarily imply that it is mechanistically relevant and important for cell death. Prior studies have suggested that bortezomib has an antitumor effect by inhibition of antiapoptotic proteins (e.g., NFκB and Bcl2), stabilization of tumor suppressors (e.g., p53), disruption of cell cycle, dysregulation of Fas or tumor necrosis factorrelated apoptosis-inducing ligand pathways, increases in reactive oxygen species (ROS), stabilization of Myc and Noxa, and induction of endoplasmic reticulum (ER) stress, any of which may trigger cell death (1) (2) (3) (4) . Despite the pleiotropic effects of proteasome inhibition, bortezomib is an effective cancer chemotherapy which exploits key weaknesses that differentiate tumor cells from normal cells. Determining the primary mechanisms by which bortezomib induces tumor cell death would increase our understanding of these key weaknesses and allow for better utilization of bortezomib in the clinic.
RNA interference (RNAi) has been widely adopted for functional genomic studies, including defining drug mechanism (5) . Genome-wide RNAi allows for different mechanisms to be ranked against each other, providing an evaluation of their relative phenotypic dominance. Some limitations of RNAi are that protein knockdown is transient, never results in complete elimination of the protein, and has various degrees of off-target effects. Genetic redundancy may also mask the phenotype of targeted genes. Nevertheless, RNAi studies have provided powerful insights into drug mechanism (6) (7) (8) .
Bortezomib induces death of most cell lines in culture within 72 hours, with an LC 50 of ∼10 nmol/L. We performed the genome-wide siRNA screen to identify genes whose knockdown affected the cytotoxicity of bortezomib using the colon cancer cell line HCT-116 because of its highly reproducible sensitivity to bortezomib and high transfectability when compared with other cell lines. The effect of the top hits from the screen were also compared in A375 and HeLa cells, highly transfectable lines derived from melanoma and cervical cancer, respectively.
Herein, we show that bortezomib leads to cell death by interfering with ribosome function, essential DNA damage pathways, and dysregulation of Myc. In particular, we examine the effect of bortezomib on protein translation initiation, especially eIF2α and mammalian target of rapamycin (mTOR), the effect of upregulation of Myc and ODC1 on polyamine homeostasis, and DNA damage signaling. In addition, we show that a common set of 39 genes is responsible for conferring sensitivity to proteasome inhibition in multiple cell lines. Although these results do not account for differences in bortezomib efficacy across tumor types seen in the clinic and cannot account for the effect of the tumor microenvironment on bortezomib sensitivity, they provide a foundation for future studies exploring these issues.
Materials and Methods
Genome-wide screen and hit deconvolution HCT-116 cells were transfected with 15 nmol/L siRNA oligos (siGENOME SMARTpool, Dharmacon) using DharmaFECT 2 (DH2) reagent (Dharmacon) in Opti-MEM (Invitrogen) in a BioCoat poly-D-lysine (PDL)-coated 384-well daughter plates (BD Biosciences). Forty-eight hours after transfection, cells were treated with 0, 4, or 7 nmol/L bortezomib and incubated for a further 48 hours, after which viability was assessed using ATPlite reagent (Perkin-Elmer) and luminescence was measured using a LEADseeker imaging system (GE Healthcare).
SMARTpool hits were deconvoluted in HCT-116, A375, and HeLa cells again in sextuplicate, except that CELLCOAT 384-well PDL-coated black, clear-bottom plates (Greiner) were used. For HCT-116 on the Greiner plates, DH2 lipid was reduced from 0.075 to 0.057 μL/well. Bortezomib was modestly more potent under these conditions, so concentrations of 2 nmol/L (LC 15 ) and 5 nmol/L (LC 60 ) were used. For A375, changes included the use of DharmaFECT 4 (DH4) transfection reagent at 0.07 μL/well, 300 cells per well, and bortezomib treatments at 4 nmol/L (LC 5 ) and 7 nmol/L (LC 55 ). For HeLa, changes included the use of DharmaFECT 1 (DH1) transfection reagent at 0.2 μL/well, 900 cells per well, and bortezomib treatments at 12 nmol/L (LC 25 ) and 25 nmol/L (LC 50 ). Bortezomib will be provided to qualified researchers once a standard Materials Transfer Agreement has been executed.
Western blot and immunoprecipitation
HCT-116 cells were treated with 30 nmol/L bortezomib (LC 90 ) or vehicle (0.1% DMSO) for the times indicated. Samples were prepared for SDS-PAGE and quantitative immunoblot analysis with antisera as specified in the Supplementary Data using tubulin as a normalization control (Supplementary Fig. S2B ). Myc was immunoprecipitated using anti-Myc agarose beads (Novus Biologics) from HCT-116 cells that had been treated for 8 hours with either 0.1% DMSO or 30 nmol/L bortezomib. Associated Myc (Epitomics) and Max (Santa Cruz Biotechnology) were quantified using an Odyssey Infrared Imager (LI-COR Biosciences).
Myc reporter assay
Myc activation was measured by transfection of HCT-116 cells with the Cignal Myc-responsive luciferase reporter (SABiosciences) that is under the control of a minimal cytomegalovirus (CMV) promoter and tandem repeats of the E-box sequence using pCMV firefly luciferase for normalization. Forty-eight hours after transfection, cells were treated with 30 nmol/L bortezomib or vehicle for the indicated times under normal or serum-starved conditions, after which luciferase activities were determined using Dual-Glo reagents (Promega) as described in the Supplementary Data.
Polyamine high-performance liquid chromatography assay Polyamines were quantified by high-performance liquid chromatography on an AccQTag column using the AccQTag method (Waters) with a modified acetonitrile gradient as specified in the Supplementary Data.
Data treatment and statistics
All ATPlite fluorescence intensity values were log 2 transformed (V). The Bliss Independence (BI) scores were calculated from the log 2 -transformed data as
where V xn is the mean of RNAi oligos treated with 4 nmol/L (or 7 nmol/L) bortezomib, V g0 is the mean of GL2 control cells, V gn is the mean of GL2 cells treated with 4 nmol/L (or 7 nmol/L) bortezomib, and V x0 is the mean of RNAi oligos treated with 0 nmol/L bortezomib.
The Rescue scores were calculated using log 2 -transformed data as min(V gn , V x0 ) − V xn .
The SE was calculated for each of the equation variables. These estimates were then squared, and the square root of their sum was taken to give the SE of the score. Probabilities that gene knockdown was on target were calculated by using hypergeometric distribution function based on deconvoluted oligo data as specified in the Supplementary Data.
Results

Design of screen
Gene knockdown in HCT-116 by 15 nmol/L Dharmacon SMARTpool siRNA was allowed to progress for 48 hours to provide for adequate depletion of protein, followed by 48 hours with two concentrations of bortezomib (LC 15 and LC 60 at 48 h) or a vehicle control. These concentrations allow for the evaluation of either enhancement or suppression of bortezomib-induced cell death by the SMARTpools, by which both activators and inhibitors of key pathways can be detected. The genome-wide screen was performed with 21,062 SMARTpools in duplicate. Three thousand eight hundred and seventy-seven SMARTpool hits were selected from the primary screen and rescreened in sextuplicate ( Supplementary Fig. S1A ).
The scoring of the screen using BI assumptions (see Supplementary Results) enabled assignment of phenotypes to the siRNAs, namely, synthetic lethality, suppressor, or epistasis ( Supplementary Fig. S1B and C) . The magnitude of the BI score indicates the relative importance of the effect for the induction and execution of cell death, although this ranking is confounded by the efficiency with which the oligos are able to knock down their respective mRNAs and ultimately reduce protein levels. It remains a formal possibility that differences in knockdown efficiency rather than target biology will be a primary determinant of interaction strength. Nevertheless, because knockdown efficiency is likely to be random across pathways, it is anticipated that pathways can be ranked by this approach provided that at least some proteins within each pathway are efficiently knocked down.
Behavior of SMARTpools
At clinically relevant concentrations (i.e., low nanomolar; ref. 9), bortezomib selectively inhibits the proteasome, primarily through the β5 subunit (PSMB5, chymotrypsin-like protease) but also the β1 subunit (PSMB6, caspase-like protease or PGPH; ref. 10). Therefore, the behavior of SMARTpools targeting proteasome subunits is of particular interest. From the genome-wide screen, 7% of all SMARTpools had viabilities of <15% relative to the GL2 negative control. In contrast, 14 of 14 SMARTpools targeting 20S core subunits had viabilities of <15% ( Fig. 1A ; Supplementary Table S3A ). Thus, the proteasome is critically required for viability. Because all SMARTpools targeting constitutive proteasome subunits had similar effects on viability, the concentration of 15 nmol/L SMARTpool seems adequate for genome-wide screening in HCT-116.
Because proteasome subunit knockdown leaves few viable cells, evaluation of the interaction of proteasome RNAi with bortezomib may be compromised. Contrary to this expectation, 14 of 14 SMARTpools targeting 20S core subunits were synthetic lethal (BI = −0.46 to −1.99 at 4 nmol/L bortezomib), indicating that knockdown of 20S core subunits sensitized the cell to bortezomib (Fig. 1A) . Strong scores were obtained even when the SMARTpool alone reduced viabilities to <5% (e.g., PSMA1, BI = −1.17 ± 0.08 with 3% viability). Because the data for the 20S core subunits are highly consistent, this indicates that useful drug interaction data can be obtained even at viabilities <5%. Because <1% of the SMARTpools in the primary screen gave viabilities <5%, SMARTpools with low viabilities were not excluded from further analysis.
Stabilization of proteins by inhibition of the proteasome is expected to be the proximal determinant of bortezomibinduced cell death, both by inducing unfolded protein stress and by stabilizing proapoptotic proteins. Indeed, cycloheximide abrogates bortezomib-induced apoptosis (11, 12) . Based on this result, knockdown of ribosome subunits should result in resistance to proteasome inhibition by reducing the rate of protein synthesis and the accumulation of proteins.
Of In contrast to the expectation that ribosome activity would be required for cell death induced by bortezomib, of 76 significant SMARTpools targeting ribosome subunits, only RNAi targeting most 40S ribosome subunits scored as epistatic at 7 nmol/L bortezomib. C, 60S ribosome subunits. RNAi targeting most 60S ribosome subunits scored as epistatic. Supporting data are included in Supplementary  Table S3A . Columns, mean (n = 6); bars, SE. CLTB  FANCE  YY1  PSMA5  BCL2L1  RASAL2  SEC61G  IDE  HNF1B OSBPL6  RNF10  HSPA14  NDUFA13  H2AFX  SPI1  PSMB5  CFLAR  CLASP1  RYR1  MAPK3 FOXH1  MGST2  SKIV2L  HAGH  BTG1  SRM  E4F1  BAD  PDLIM7  ATF6  ENPP1 TGFB1  SS18L1  VPS35  EIF5A  UBA3  BAT3  ARHGEF1  ATP2A3  KCNQ2  SNX8  TRRAP†   VPS28  FAS  CDC42EP1*  PTH2  NFE2L2  FASTK  CENPB  GSTZ1 LGALS1 VPS4A MTHFR FOXO4* TAF11* DAK* NOTE: Pathway modules inferred from genetic interactions of genes confirmed by deconvolution in colon cancer cell line HCT-116. Genes had hypergeometric P < 0.05, except as indicated. Genes are ordered by increasing P values. All genes included in the table interacted with bortezomib with P < 0.10 in at least one cell line. Underlined genes had similar phenotypes in HCT-116, A375, and HeLa cell lines. Eight hits with low expression data in HCT-116 were CLASP1, EIF3A, ENPP1, FOXH1, HNF1B, MTHFR, SORBS1, and SPI1 (Supplementary Table S3C) . Abbreviations: HR, homologous recombination; TGFβ, transforming growth factor β. *P < 0.10. RPS8 and RPL5 knockdown gave significant rescue, suggesting an off-target effect with these two pools. The very consistent lack of significant rescue indicating epistasis suggests that inhibition of protein translation and proteasome inhibition by bortezomib result in related stresses to the cell (see Discussion).
Deconvolution of genome-wide hits
Because of the pleiotropic effect of proteasome inhibition by bortezomib, the frequency of interactions due to off-target effects of the SMARTpools was anticipated to be substantial. To determine the likelihood that the phenotype was due to knockdown of the target, the individual oligos making up each SMARTpool were further evaluated (four oligos per gene at 4 nmol/L individual oligo). Eight hundred and sixtyeight genes were selected based on the screen results or prior literature. Because of the coherence of their data, proteasome and ribosome subunits were underrepresented in this deconvolution set. The oligos making up the selected SMARTpools were individually evaluated for interaction with bortezomib in sextuplicate (Supplementary Table S3B ). The top 160 hits were rearrayed and evaluated again in sextuplicate. Finally, these top 160 hits were reassayed twice using an updated set of individual oligos (Supplementary Table S3C) .
One hundred genes gave significant results in HCT-116 based on a hypergeometric evaluation of the deconvoluted oligo data ( Table 1 ). The 100 genes were classified into pathway modules using their gene annotation (Supplementary  Table S3D ). Based on the statistical approach used to validate hits, it is anticipated that 5 to 10 hits within Table 1 are false positives.
Genes whose siRNAs score as suppressor (Table 1) represent those whose presence is important for inducing cell death in response to proteasome inhibition; removal of these proteins protects against bortezomib-induced cell death. It is possible that these proteins are proteasome substrates that when stabilized contribute to cell death. Therefore, we investigated whether these proteins were stabilized by proteasome inhibition. ASF1B, BNIP3, Gadd45α, Myc, ODC1, PMAIP1 (Noxa), p-SMC1A, SREBF1, and p53 showed increases in protein levels following bortezomib treatment (Fig. 2) . ATG4A, BAX, BXDC2, DDX27, EIF4E, EIF4G1, SETX, SNIP1, and SORBS1 did not show clear increases ( Supplementary  Fig. S2A ).
Genes associated with pathway modules were explored in more detail, focusing on ribosome biogenesis and translation, Myc/polyamine, and homologous recombination (HR). Among the translation pathway genes, phosphorylation of targets of mTORC1, namely 4EBP1 (pS65) and S6K (pT389), both decreased following bortezomib treatment (Fig. 3A) . Both the pT37/pT46 and total 4EBP1 antibodies indicate that 4EBP1 shifts toward the hypophosphorylated form. In agreement with ribosome knockdown being epistatic with bortezomib, we have found that cycloheximide is epistatic with bortezomib in HCT-116 viability and does not rescue cells (Fig. 3B) . The phosphorylation of Ser 51 on EIF2S1 (eIF2α) decreased probably due to increases in PPP1R15A (Gadd34) levels (Fig. 3C ).
Myc pathway gene Max was modestly affected by bortezomib treatment (Fig. 4A) . Immunoprecipitation of Myc coprecipitates Max but bortezomib treatment does not result in a commensurate increase in associated Max (Fig. 4B) . A Myc reporter assay showed that the stabilization of Myc results in increased transcriptional activity both in the presence and in the absence of serum (Fig. 4C) . ODC1, a target of Myc, is increased (Fig. 2) and the product of ODC1, putrescine, showed a marked increase following bortezomib treatment (Fig. 4D) .
Evidence was collected suggesting that bortezomib as a single agent potentiates DNA damage signaling. HR pathway gene RAD51 showed increases following bortezomib treatment. The phosphorylation of SMC1A (pS957), TP53 (pS15), H2AFX (pS139), and CHEK2 (pT68) on their ATM sites and the ubiquitination of FANCD2 were also increased by bortezomib, particularly at 18 and 24 hours, whereas MDC1 and RAD21 levels were unaffected (Figs. 2 and 5 ). The phosphorylation of CHEK1 (pT317) on its ATR site was modestly increased. Table 1 was determined by Western blot on HCT-116 treated with vehicle (0.1% DMSO, top blot) or 30 nmol/L bortezomib (LC 90 concentration, bottom blot). The control lanes 8 and 9 (24-h treatment) show that exposure of the film for the top and bottom blots was equivalent. Phosphorylation of SMC1A and TP53 on their ATM sites was also evaluated. Full-length SREBF1 is indicated by the arrowhead. Two bands that are consistent with activation of the two spliceforms of SREBF1 by MBTPS1 (S1P) and MBTPS2 (S2P) are indicated by the two bars. Full-length blots are presented in Supplementary Fig. S8 , along with theoretical molecular weights of the proteins.
Evaluation of hits in other cell lines and with other proteasome inhibitors
More than half of the 100 genes interacting with bortezomib in HCT-116 gave similar phenotypes in the melanoma cell line A375 (Supplementary Table S1 ) or in the cervical cancer cell line HeLa (Supplementary Table S2 ). Notably, the knockdown of 39 genes gave similar phenotypes in all three cell lines (underlined genes in Table 1 ). Therefore, although details of the induction of cell death probably vary between cell lines, these results indicate the existence of common themes. These common themes include translation initiation, Myc/polyamines, and key ubiquitin pathway genes.
The individual oligos for each of the 100 genes interacting with bortezomib behaved consistently with multiple classes of proteasome inhibitors in HCT-116 cells. RNAi interactions with the peptidyl boronate MLN2238, the peptide ML912, and the epoxide epoxomicin were highly correlated (r 2 = 0.86-0.91) with interactions with bortezomib ( Supplementary  Fig. S3 ). The interactions with the β-lactone salinosporamide A were less correlated (r 2 = 0.69-0.70), although still much more correlated than those for MLN4924 (r 2 < 0.11), a Nedd8-activating enzyme inhibitor, or thapsigargin (r 2 < 0.18), an inhibitor of the SERCA pumps and an inducer of ER stress.
Discussion
The 100 genes within Table 1 highlight the critical biology involved in the response of HCT-116 cells to bortezomib. We have chosen to focus on candidate proteasome substrates and pathway modules where new biology has been identified that had not previously been characterized as being critical for proteasome inhibition-induced cell death, specifically mTOR inhibition, polyamine dysregulation, and potentiation of DNA damage signaling. A comprehensive analysis of the role of all of the genes within Table 1 will await further Cotransfection of Renilla luciferase showed that viability was unaffected over 8 h. Addition of bortezomib, either in the presence or in the absence of serum, showed a significant increase in Myc transcription activity. Fold induction is relative to the vehicle control. D, HCT-116 cells were treated with vehicle (0.1% DMSO, dashed line) or 30 nmol/L bortezomib (solid line) for the time course indicated. A significant increase in putrescine levels was seen within 4 h, whereas no significant changes were seen in spermidine until levels were decreased at 24 h. Full-length blots are presented in Supplementary Fig. S8 , along with theoretical molecular weights of the proteins. studies. Our results do support some previously suggested mechanisms, including key roles for ER stress, p53, and Myc. Surprisingly, we do not see evidence for the critical involvement of ROS, NFκB, activator protein-1, or cell cycle proteins in HCT-116. We have provided some initial RNAiindependent data to substantiate suggested pathway involvement. Below, we suggest the context within which these interactions are occurring. Additional modules are explored in Supplementary Results. Specifically, regulation of apoptotic proteins by bortezomib is presented in Supplementary  Fig. S4 . In addition, we show that BNIP3 stabilization does not seem to result in ROS or mitophagy as shown in Supplementary Figs. S4 to S7. Although not all phenotypes that bortezomib might affect (growth arrest, apoptosis, necrosis, autophagy, and senescence) will be equally captured by the ATPlite viability assay used in this screen, these results represent a genome-wide evaluation of genetic sensitivity within the inherent biases of that assay.
Proteasome subunits
Knocking down the 20S core subunits of the proteasome gave a synthetic lethal phenotype (Table 1; Fig. 1 ). These data indicate that the function of the 20S core subunits compensates for bortezomib-induced cell death. RNAi against 20S proteasome subunits reduces the number of proteasome active sites, and less bortezomib is needed to reduce proteasome function below a critical limit. Therefore, these data are consistent with bortezomib inducing cell death by binding to the 20S core directly.
Ribosome subunits and translation
Broadly speaking, oligos affecting ribosome function scored as epistatic in the screen (Table 1; Fig. 1 ), contrary to the expectation that inhibition of the ribosome should prevent the buildup of cytotoxic proteins caused by proteasome inhibition. This result suggests that inhibition of ribosome function induces a stress similar to inhibition of proteasome function. Indeed, an epistatic interaction between protein translation and the ubiquitin-proteasome system has been shown previously in yeast; inhibition of either results in the toxic depletion of free ubiquitin pools (14) .
Three of the genes with suppressor oligos are involved in translation initiation, EIF4E, EIF4G1, and PPP1R15B (CReP, constitutive repressor of eIF2α phosphorylation), suggesting that the activity of these genes is important for induction of cell death by bortezomib. eIF4E binds the cap structure of mRNA and, in a complex with eIF4A and eIF4G, recruits the mRNA to the ribosome. mTOR promotes protein synthesis in part by phosphorylating 4EBP1, reducing its ability to compete with eIF4G binding to eIF4E. HCT-116 cells are resistant to mTOR inhibition due to downregulation of 4EBP1 protein levels, reducing its ability to inhibit eIF4E (15) . Our data suggest that siRNA against eIF4E could reduce eIF4E levels sufficiently that 4EBP1 would be capable of inhibiting protein translation. This inhibition would prevent protein accumulation following proteasome inhibition, rescuing the cells from bortezomib-induced apoptosis. Therefore, the EIF4E and EIF4G1 hits suggest that bortezomib induces mTOR inhibition but that, in HCT-116 cells, this inhibition is unable to inhibit protein synthesis. In fact, bortezomib treatment does shift 4EBP1 to the inhibitory hypophosphorylated form (Fig. 3A) . Phosphorylation of S6K is also inhibited, consistent with mTOR inhibition. These data agree with a recent publication (16) . Many tumor cells have dysregulated protein translation inhibition (17) . In contrast, normal cells should respond to this bortezomib-induced mTOR inhibition with a reduction in protein translation, suggesting a rationale for the therapeutic window of bortezomib.
The other suppressor hit, PPP1R15B, is the constitutive form of the inducible PPP1R15A (Gadd34). Although we were not able to evaluate PPP1R15B levels, PPP1R15A was increased quite dramatically (Fig. 3C ). Both are regulatory subunits for protein phosphatase 1, targeting EIF2S1 (epistatic gene, also known as eIF2α) for dephosphorylation. Phosphorylation of EIF2S1 results in general translation inhibition, although some stress response mRNAs are still translated (17) . It is possible that the translation of these stress mRNAs is involved in the induction of apoptosis. Salubrinal, an inhibitor of EIF2S1 dephosphorylation, promoted cell death following bortezomib treatment (18) . Thus, phosphorylated EIF2S1 is important for induction of cell death by bortezomib. In many multiple myeloma cell lines, bortezomib induces a robust and long-lived phosphorylation of Figure 5 . Bortezomib potentiates DNA damage signaling. Regulation of proteins was determined in the same manner as Fig. 2 . Markers of DNA damage response, including RAD51 stabilization and phosphorylation of H2AFX and CHEK2 at their ATM sites, are increased following bortezomib, whereas CHEK1 phosphorylation at its ATR site is upregulated more modestly. Monoubiquitination of FANCD2 (top band) is increased relative to the unmodified FANCD2 (bottom band) beginning at 12 h. MDC1, the three closely spaced bands above 247 kDa, is not clearly differentially regulated between vehicle and bortezomib treatment, contrary to prior reports (31) . Neither full-length nor separase-cleaved fragments of RAD21 increase following bortezomib treatment. Full-length blots are presented in Supplementary Fig. S8 , along with theoretical molecular weights of the proteins.
EIF2S1 (19) , consistent with this tumor type being particularly sensitive to bortezomib.
Under hypoxic conditions, phosphorylation of EIF2S1 provides acute and general translation inhibition, but this is lost following the induction of PPP1R15A. More chronic translation inhibition is provided by inhibition of the mTOR pathway, possibly via upregulation of BNIP3 or DDIT4 (Redd1; ref. 17) . Recent work suggests that induction of DDIT4 is important for bortezomib resistance in multiple myeloma (20) . In this way, bortezomib mimics hypoxia and hypoxia resistance may predict sensitivity to bortezomib.
Myc
Myc stabilization and its induction of PMAIP1 (Noxa) have previously been proposed to be critical for cell death following proteasome inhibition (21) . Myc, ODC1, and PMAIP1 are substantially increased by proteasome inhibition (Fig. 2) . ODC1 (ornithine decarboxylase) is both a known substrate of the proteasome and relatively strongly induced target of Myc (22, 23) . Surprisingly, the oligo targeting SRM (spermidine synthase) is synthetically lethal with bortezomib, suggesting that the intermediate between ODC1 and SRM (i.e., putrescine) is increased by bortezomib and, at least in this setting, toxic. The oligo targeting EIF5A, which is modified by spermidine (24) , is also synthetically lethal with bortezomib, suggesting that putrescine affects the modification of elF5A as well. We have observed a significant increase in putrescine levels in bortezomib-treated cells (Fig. 4D) , followed by a significant drop in spermidine levels at 24 hours. Proteasome inhibition by MG-132 or lactacystin has previously been shown to prevent modification of eIF5A by spermidine (25) . Excess putrescine accumulation has been shown to inhibit the modification of eIF5A (26) , suggesting that bortezomib blocks eIF5A modification by increasing putrescine levels.
Myc, which regulates 15% of the genome (27) , controls multiple steps within protein translation, including ribosome biogenesis and translation initiation, glycolysis, mitochondrial homeostasis, polyamine biosynthesis, and iron metabolism (23) . Myc has also been shown to cooperate with eIF4E in transformation (28) . Therefore, stabilization of Myc may play a role in all of the modules identified in this study and may thus be a central player within bortezomib-induced death of HCT-116 cells.
Homologous recombination
Many genes associated with HR have oligos that give significant phenotypes within the screen. This result suggests that the function of HR is important to cell death following bortezomib treatment. We have shown that bortezomib potentiates DNA damage signaling as a single agent (Fig. 3) . Prior studies (29) (30) (31) have shown that bortezomib can block HR following DNA damage by another agent. We suggest that bortezomib also blocks DNA damage repair of double-stranded breaks occurring during normal replication.
A recent phase 3 trial in multiple myeloma showed that the combination of bortezomib with melphalan-prednisone was superior to melphalan-prednisone alone (32) . Melphalan resistance is dependent on HR (33, 34) . The ability of bortezomib to inhibit HR could help to explain the clinical superiority of this combination, in agreement with recent studies in multiple myeloma cells (35) , although we did not see reductions in FANCD2 protein levels.
In conclusion, the genome-wide RNAi study of the determinants of bortezomib sensitivity suggests multiple mechanisms by which proteasome inhibition results in cell death. Ribosome function is inhibited following proteasome inhibition, particularly translation initiation. Tumor cells have dysregulated translation inhibition and so are not fully protected by this homeostatic response. Myc stabilization promotes protein translation, inducing further stress in the tumor cell, as well as inducing the accumulation of putrescine. BNIP3 is also stabilized, although the downstream effectors are unclear. The repair of DNA damage, probably originating from normal S-phase replication, is inhibited. Stabilization of p53 promotes cell death. ER stress also seems to contribute to cell death. Because multiple homeostatic responses are inhibited, the tumor cell engages programmed cell death. Our initial data are in support of these mechanistic hypotheses and further studies will be needed to confirm these insights. We anticipate that such studies will improve the selection of new targets, the design of pharmacodynamic biomarkers, and the application of combination chemotherapy regimens containing bortezomib.
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